reviewosteoporosistransplantation of the lungsterminal pulmonary pathology1.Cunningham J. Postransplantation bone Disease. Transplantation 2005; 79: 629-634.2.Гельцер Б. И., Кочеткова Е. А., Невзорова В. А., Коновалова Е. Н. Остеопороз как проблема пульмонологии. Тер. арх. 2000; 12: 71-73.3.Чучалин А. Г. Хронические обструктивные болезни легких. М.: Медицина; 1998.4.Papaioannou A., Parkinson W., Ferko N. et al. Prevelence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos. Int. 2003; 14: 913-917.5.Biskobing D. M. COPD and osteoporosis. Chest 2002; 121 (2): 609-620.6.Incalzi R. A., Caradonna P., Ranieri P. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir. Med. 2000; 94: 1079-1084.7.Engelen M. P. K. J., Schols A. M. W. J., Heidendal G. A. K. et al. Dual-energy X-ray absorptiometry in the clinical evaluation of body composition and bone mineral density in patients with chronic obstructive pulmonary disease. Am. J. Clin. Nutr. 1998; 68: 1298-1303.8.Aris R., Neuringer I., Weiner M., Ontjes D. Severe osteoporosis before and after lung transplantation. Chest 1996; 109: 1176-1183.9.Richy F., Bousquet J., Ehrlich G. E. et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos. Int. 2003; 14: 179-190.10.Caplan-Shaw C. E., Arcasoy S. M., Shawe E. et al. Osteoporosis in diffuse parenchymal lung disease. Chest 2006; 129: 140-146.11.Taveira-Dasilva A. M., Stylianou M. P., Hedin C. J. et al. Bone mineral density in lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 2005; 171: 61-67.12.Dosanjh A. A review of nutritional problems and the cystic fibrosis lung transplant patient. Pediatr. Transplant. 2002; 6: 388-391.13.Aris R., Lester G., Ontjes D. Treatment of bone disease in cystic fibrosis. Curr. Opin. Pulm. Med. 2004; 10: 524-530.14.Tschopp O., Schmid C., Speich R. et al. Pretransplantation bone disease in patients with primary pulmonary hypertension. Chest 2006; 129: 1002-1008.15.Ott S. M., Aitken M. L. Osteoporosis in patients with cystic fibrosis. Clin. Chest Med. 1998; 19: 555-567.16.Cahill B. C., O'Rourke M. K., Parker S. et al. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation 2001; 72: 1251-1255.17.Epstein S., Shane E. Transplantation osteoporosis. In: Marcus R., Feldman D., Kelsey J. (eds). Osteoporosis. 2nd ed. New York: Academic Press; 2001. 327-235.18.Rodino M. A., Shane E. Osteoporosis after organ transplantation. Am. J. Med. 1998; 104: 459-469.19.Cohen A., Shane E. Transplantation osteoporosis. Curr. Opin. Endocrinol. Diabet. 2001; 8: 283-290.20.Atsumi K., Kushida K., Yamazaki K. et al. Risk factors for vertebral fractures in renal osteodystrophy. Am. J. Kidney Dis. 1999; 33: 287-293.21.Muchmore J. S., Cooper D. K. C., Ye Y. et al. Loss of vertebral bone density in heart transplant patients. Transplant. Proc. 1991; 23: 1184-1185.22.Monegal A., Navasa M., Guanabens N. et al. Bone mass and mineral metabolism in liver transplant patients treated FK506 or cyclosponne A. Calcif. Tissue Int. 2001; 68: 83-86.23.Trombetti A., Gerbase M. W., Spiliopoulos A. et al. Bone mineral density in lung transplant recipient before and after graft: prevention of lumbar post-transplantation-accelerated bone loss by pamidronate. J. Heart Lung Transplant. 2000; 19: 736-743.24.Spira A., Gutierrez C., Chaparro C. et al. Osteoporosis and lung transplantation: a prospective study. Chest 2000; 117: 476-481.25.Shane E., Papandopoulos A., Staron R. B. et al. Bone loss and fracture after lung transplantation. Transplantation 1999; 68: 220-227.26.Julian B. A., Laskow D. A., Dubovsky J. et al. Rapid loss of vertebral mineral density after renal transplantation. N. Engl. J. Med. 1994; 1 (9): 1-9.27.Horber F. F., Casez J. P., Steiger U. et al. Changes in bone mass early after kidney transplantation. J. Bone Miner. Res. 1994; 4: 2-9.28.Sambrook P. N., Kelly P. J., Keogh A. et al. Bone loss after cardiac transplantation: a prospective study. J. Heart Lung Transplant. 1994; 13: 116-121.29.Shane E., Rivas M. D., Silverberg S. J. et al. Osteoporosis after cardiac transplantation. Am. J. Med. 1993; 94: 257-264.30.Meys E., Fontanges E., Foureade N. et al. Bone loss after orthotropic liver transplantation. Am. J. Med. 1994; 97: 445-450.31.Thiйbaud D., Krieg M. A., Gillard-Berguer D. et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur. J. Clin. Invest. 1996; 26: 549-555.32.Glendenning P., Kent G. N., Adler B. D. et al. High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Clin. Endocrinol. (Oxf.) 1999; 50: 347-355.33.Leidig-Bruckner G., Hosch S., Dodidou P. et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357: 342-347.34.Trulock E. P., Christie J. D., Edwards L. B. et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report - 2007. J. Heart Lung Transplant. 2007; 26: 782-795.35.Shane Е., Epstein S. Transplantation osteoporosis. Transplant. Rev. 2001; 15: 11-16.36.Shane E., Silverberg S. J., Donovan D. et al. Osteoporosis in lung transplantation candidates with end stage pulmonary disease. Am. J. Med. 1996; 101: 262-269.37.Aris R. M., Renner J. B., Winders A. D. et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann. Intern. Med. 1998; 128: 186-193.38.Ferrari S. L., Nicod L. P., Hamacher J. et al. Osteoporosis in the patients undergoing lung transplantation. Eur. Respir. J. 1996; 9: 2378-2382.39.Dodd V. A., Staron R. B., Papadopoulos A. et al. Bone densitometry should be included in the evaluation of candidates for lung transplantation. J. Transplant. Coord. 1999; 9: 119-123.40.Насонов Е. Л., Гукасян Д., Насонова М. Б. Иммунопатология ревматоидного артрита и остеопороз: новые данные. Остеопороз и остеопатии 2000; 2: 4-8.41.Gluck О., Colice G. Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary disease. Chest 2004; 125: 1859-1876.42.Canalis E., Delany A. M. Mechanisms of glucocorticoid action in bone. Ann. N. Y. Acad. Sci. 2002; 996: 73-81.43.Golstein M. F., Fallon J. J., Harning A. Jr. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 1999; 116: 1733-1749.44.Teitelbaum S. L. Bone resorption by osteoclasts. Science 2000; 289: 1504-1508.45.Weinstein R. S., Manolagas S. C. Apoptosis and osteoporosis. Am. J. Med. 2000; 108: 153-164.46.Dougall W. C., Chaisson M. The RANKL/RANK/OPG triad in cancer-induced bone diseases. Cancer Metastas. Rev. 2006; 25: 541-549.47.Regmi A., Fuson Т., Yang X. et al. Suranin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. Bone 2005; 36: 284-297.48.Baud'huin M., Lamoureux F., Duplomb L. et al. RANKL, RANK, osteoprotegerine: key partners of osteoimmunology and vascular diseases. Cell Mol. Life Sci. 2007; 64: 2334-2350.49.Monegal A., Navasa M., Peris P. et al. Serum osteoprotegerin and its ligand in cirrotic patients referred for osteoporotic liver transplantation: relationship with metabolic bone disease. Liver Int. 2007; 5: 492-497.50.Hofbauer L. C., Brueck C. C., Shanaham C. M. et al. Vascular calcification and osteoporosis - from clinical observation towards molecular understanding. Osteoporos. Int. 2007; 18: 251-259.51.Smith J. M., Nemeth Th. L., McDonald R. A. Current immunosupressive agents in pediatric renal transplantation. Efficacy, side-effects and utilization. Pediatr Transplant. 2002; 8: 445-453.52.Sass D. A., Bowman A. R., Yuan Z. et al. Alendronate prevents cyclosporine A-induced osteopenia in the rat. Bone 1997; 21: 65-70.53.Stein В., Takizawa M., Katz I. et al. Salmone calcitonin prevents cyclosporine A-induced high turnover bone loss. Endocrinology 1991; 129: 92-98.54.Lutz F., Klemens В., Duska D. et al. Testosterone concentrations and sirolimus in male renal transplant patients. Am. J. Transplant. 2004; 4: 130-131.55.Sehgal S. N. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther. Drug Monit. 1995; 17: 660-664.56.Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents on the skeleton. J. Bone Mineral Res. 1996; 11: 1-7.57.Inoue Т., Kawamura I., Matsuo M. et al. Lesser reduction in bone mineral density by the immunosuppressant, FK 506, compared with cyclosporine in rat. Transplantation 2000; 70: 774-779.58.Movsowitz С., Epstein S., Fallon M. Cyclosporin A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571-2577.59.Hofbauer L. C., Shui C., Riggs B. L. et al. Effects of immunosuppresants on receptor activator of NF-kappa В ligand and osteoprotogerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 2001; 280: 334-337.60.Campistol J. M., Holt D. W., Epstein S. et al. Bone metabolism in renal transplant patients treated with cyclosporine or syrolimus. Transplant. Int. 2005; 18: 1028-1035.61.Goffin E., Devogelaer J. P., Depresseux G. et al. Osteoporosis after organ transplantation [letter]. Lancet 2001; 357: 1623.62.Laet De C., Kanis J. A., Odйn A. et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos. Int. 2005; 16: 1330-1338.63.Willing R., Luukinen H., Jalovaara P. Factors related to occurrence of hip fractures during a fall on the hip. Publ. Hlth 2003; 117: 25-30.64.Brown J. P., Josse R. G. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can. Med. Assoc. J. 2002; 167 (10): 1-34.65.Iqbal F., Michaelson J., Thaler L. et al. Declining bone mass in men with chronic pulmonary disease. Contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 1999; 116: 1616-1624.66.Bolton C. E., Ionescu A. A., Shiels K. M. et al. Associated loss fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170 (12): 1286-1293.67.Kochetkova E. A., Kessler R., Metivier A. C. et al. Bone mineral density in patients with end-stage lung disease (abstract). Osteoporos. Int 2008; 28 (suppl. 1): 108.68.Gregg E. W., Cauley J. A., Seeley D. G. et al. Physical activity and osteoporotic fracture risk in older women. Ann. Intern. Med. 1998; 129: 81-88.69.Gregg E. W., Cauley J. A., Seeley D. G. et al. Physical activity and osteoporotic fracture risk in older women. Ann. Intern. Med. 1998; 129: 81-88.70.Krall E. A., Dawson-Hughes B. Walking is related to bone density and rates of bone loss. Am. J. Med. 1994; 96: 20-26.71.Vrieze A., Greef de H. M., Wykstra P. J. et al. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos. Int. 2007; 18: 1197-1202.72.Jorgensen N. R., Schwarz P., Holme I. et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease. - A crosse sectional study. Respir. Med. 2006; 4: 34-38.73.Karadag F., Cildag O., Yurekli Y. et al. Should COPD patients be routinely evaluated for bone mineral density? J. Bone Miner. Metab. 2003; 21: 242-246.74.Dimai H. P., Domej W., Leb G. et al. Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia. J. Bone Miner. Res. 2001; 16: 2132-2141.75.Clowes J. A., Riggs S. K., Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev. 2005; 208: 207-227.76.Yasuda N., Coton K., Minatoguhi S. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir. Med. 1998; 92 (8): 993-998.77.Demer L. L., Tintut Y., Abedin M. Role of inflammation in atherosclerotic calcification, metaplasia and osteoporosis. Wld Hlth Org. Int. Congr. Ser. 2004; 1262: 570-573.78.Fitzpatrik L. A., Turner R. T., Ritman E. R. Endochondral bone formation in the heart: a possible mechanism of coronary calcification. Endocrinology 2003; 144 (6): 2214-2219.79.Parhami F., Morrow A., Balucan J. et al. Demer, lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: a possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vase. Biol. 1997; 17 (4): 680-687.